• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CorVel Announces Revenues and Earnings

    2/4/25 6:15:00 AM ET
    $CRVL
    Specialty Insurers
    Finance
    Get the next $CRVL alert in real time by email

    FORT WORTH, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announced the results for the quarter ended December 31, 2024. Revenues for the quarter were $228 million, an increase from $202 million in the December quarter of 2023. Earnings per share for the quarter were $0.46, compared to $0.33 in the same quarter of the prior year. Revenues for the nine months ended December 31, 2024 were $664 million, an increase from $588 million during the nine months ended December 31, 2023. Earnings per share for the nine months ended December 31, 2024 were $1.32, compared to $1.09 during the nine months ended December 31, 2023. The earnings per share numbers for the current and prior year have been adjusted to reflect the three-for-one stock split of its common stock which was paid on December 24, 2024.

    Third Quarter Fiscal Year 2025 Highlights 

    • Revenue increased 13% to $228 million, compared to the third quarter of fiscal year 2024.
    • Gross profit increased 25% to $52.9 million, at 23.2% gross margin, compared to the third quarter of fiscal year 2024 gross profit of $42.2 million.
    • Diluted earnings per share increased 39% to $0.46, compared to the third quarter of fiscal year 2024 diluted earnings per share of $0.33.
    • Exited the quarter with $163 million cash, cash equivalents, and no borrowings.
    • The Company repurchased $9.6 million of common stock during the quarter.

    A key to CorVel's success and differentiation in technological innovation is the development team's structure, the depth and tenure of the employees, and the lack of impedance in translating business needs into the development and implementation of functioning systems. Due to the depth and strength of the IT team, system updates, and new features are released weekly, which enables rapid progress on enhancements and advancements in automation and innovation. In the December quarter, generative-AI-based functionality was released to streamline document processing and identify claim milestones, and improvements are planned to enhance the integrated communication platform. These enhancements can optimize outcomes, improve the experience of injured workers, and make day-to-day tasks easier, which allows CorVel professionals to focus on higher-level activities.

    During the quarter in the healthcare market, the persistent upward trend of medical costs is causing Administrative Services Only, ASO, customers to seek additional medical savings and greater cost efficiency in claims. CERIS is ideally equipped to solve the growing demand by offering multiple audits and lowering claim thresholds. With substantial expertise in prepay, CERIS is able to accommodate ASOs and Payers with the tools needed to reduce medical spend without additional administrative overhead.

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

    All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company's current expectations, estimates and projections about the Company, management's beliefs, and certain assumptions made by the Company, and events beyond the Company's control, all of which are subject to change. Such forward-looking statements include, but are not limited to, improved productivity resulting from automation and augmentation across enterprise business systems. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company's actual results to differ materially and adversely from those expressed in any forward-looking statement results of operations and financial condition is greater than our initial assessment. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company's filings with the Securities and Exchange Commission, including but not limited to "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and the Company's Quarterly Report on Form 10-Q for the quarters ended June 30, 2024 and September 30, 2024. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

    CorVel Corporation

    Quarterly Results – Income Statement

    Quarters and Nine Months Ended December 31, 2024 (unaudited) and December 31, 2023 (unaudited)

    Quarter Ended December 31, 2024  December 31, 2023 
    Revenues $227,973,000  $202,303,000 
    Cost of revenues  175,115,000   160,143,000 
    Gross profit  52,858,000   42,160,000 
    General and administrative  22,058,000   19,798,000 
    Income from operations  30,800,000   22,362,000 
    Income tax provision  7,029,000   5,267,000 
    Net income $23,771,000  $17,095,000 
    Earnings Per Share:      
    Basic $0.46  $0.33 
    Diluted $0.46  $0.33 
    Weighted Shares      
    Basic  51,388,000   51,318,000 
    Diluted  52,038,000   51,978,000 



    Nine Months Ended December 31, 2024  December 31, 2023 
    Revenues $664,075,000  $588,078,000 
    Cost of revenues  512,528,000   459,788,000 
    Gross profit  151,547,000   128,290,000 
    General and administrative  64,043,000   55,786,000 
    Income from operations  87,504,000   72,504,000 
    Income tax provision  18,758,000   15,706,000 
    Net income $68,746,000  $56,798,000 
    Earnings Per Share:      
    Basic $1.34  $1.11 
    Diluted $1.32  $1.09 
    Weighted Shares      
    Basic  51,384,000   51,372,000 
    Diluted  51,999,000   52,056,000 
             

    CorVel Corporation

    Quarterly Results – Condensed Balance Sheet

    December 31, 2024 (unaudited) and March 31, 2024

      December 31, 2024  March 31, 2024 
    Cash $162,944,000  $105,563,000 
    Customer deposits  99,496,000   88,142,000 
    Accounts receivable, net  106,178,000   97,108,000 
    Prepaid taxes and expenses  14,543,000   11,418,000 
    Property, net  91,256,000   85,892,000 
    Goodwill and other assets  42,420,000   42,498,000 
    Right-of-use asset, net  21,940,000   24,058,000 
    Total $538,777,000  $454,679,000 
    Accounts and taxes payable $16,630,000  $16,631,000 
    Accrued liabilities  200,108,000   167,868,000 
    Long-term lease liabilities  21,189,000   22,533,000 
    Paid-in capital  246,698,000   233,632,000 
    Treasury stock  (822,514,000)  (793,905,000)
    Retained earnings  876,666,000   807,920,000 
    Total $538,777,000  $454,679,000 



    Contact: Melissa Storan
    Phone: 949-851-1473
    www.corvel.com


    Primary Logo

    Get the next $CRVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer O'Brien Brandon exercised 750 shares at a strike of $29.23 and covered exercise/tax liability with 472 shares, increasing direct ownership by 2% to 15,961 units (SEC Form 4)

      4 - CORVEL CORP (0000874866) (Issuer)

      5/23/25 9:32:36 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Vice President of Accounting Yoss Jennifer

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 7:02:08 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:30:11 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Leadership Updates

    Live Leadership Updates

    See more
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Announces Retirement of V. Gordon Clemons

      FORT WORTH, Texas, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announces V. Gordon Clemons is electing to retire as a member of the Company's Board of Directors (the "Board") and as Chairman of the Board, effective November 26, 2024, after 37 years of service. Clemons founded CorVel Corporation in 1988 and has served as Chairman of the Board since the Company went public in 1991. Effective upon Clemons' retirement, Michael G. Combs, the Company's President and Chief Executive Officer, was appointed as the new Chairman of the Board. Clemons has been an advisor to Combs since 2017, and he will continue to be available to Combs as an outside consultant. "Building CorVe

      11/29/24 1:30:00 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Appoints Jeff Gurtcheff Vice President of Enterprise Comp

      FORT WORTH, Texas , Feb. 02, 2022 (GLOBE NEWSWIRE) -- CorVel, a national provider of risk management solutions, has named Jeff Gurtcheff as Vice President of Enterprise Comp. With more than 30 years of experience, Gurtcheff brings a deep understanding of the industry with strategic leadership and management expertise. As Vice President of Enterprise Comp, Gurtcheff will refine product vision and strategy related to corporate goals and manage resources responsible for regulatory compliance, claims handling, quality, and standards and procedures. His position will also support product line profit growth by developing improved processes, risk management practices, and analytical reporting.

      2/2/22 7:08:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/14/24 6:45:55 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 5:02:29 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 4:05:36 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CorVel Announces Revenues and Earnings

      FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announced the results for the quarter and fiscal year ended March 31, 2025. Revenues for the quarter were $232 million, an increase from $207 million in the March quarter of 2024. Earnings per share for the quarter were $0.51, compared to $0.37 in the same quarter of the prior year.  Revenues for the fiscal year ended March 31, 2025 were $896 million, an increase from $795 million during the fiscal year ended March 31, 2024. Earnings per share for the fiscal year ended March 31, 2025 were $1.83, compared to $1.47 during the fiscal year ended March 31, 2024. The earnings per share numbers for the current an

      5/22/25 6:15:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • CorVel Earns 2025 Great Place To Work Certification™

      FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL) is proud to be Certified™ by Great Place To Work® for the fifth year in a row. The prestigious award is based entirely on what current employees say about their experience working at CorVel. Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation. "We are very pleased to be recognized as a Great Place To Work for a 5th consecutive year. CorVel is committed to being an organization where people can learn, grow, and advance, and we are grateful for the team members

      2/25/25 7:05:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    SEC Filings

    See more
    • SEC Form 10-K filed by CorVel Corp.

      10-K - CORVEL CORP (0000874866) (Filer)

      5/23/25 4:30:30 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CORVEL CORP (0000874866) (Filer)

      5/21/25 7:30:09 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/11/25 5:22:53 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance